Innoviva (NASDAQ: INVA) revenue
Innoviva reported revenue of $411.3m for fiscal 2025, 14.7% more than in fiscal 2024 ($358.7m). Since fiscal 2016 its revenue has grown by 208.0%, an average growth of 13.3% a year.
Innoviva has grown its revenue for 2 years in a row, and fiscal 2025 is the highest of its 10 fiscal years on record. The biggest drop was in fiscal 2022, −15.4%.
Embed this chart
Copy this code into your website or blog. The chart updates with each new annual report.
Revenue by fiscal year
| Fiscal year | Revenue | Change | Operating profit | Operating margin |
|---|---|---|---|---|
| 2025 | $411.3m | +14.7% | $163.7m | 39.8% |
| 2024 | $358.7m | +15.5% | $166.9m | 46.5% |
| 2023 | $310.5m | −6.3% | $113.9m | 36.7% |
| 2022 | $331.3m | −15.4% | $302.7m | 91.4% |
| 2021 | $391.9m | +16.4% | $375.1m | 95.7% |
| 2020 | $336.8m | +29.0% | $321.1m | 95.3% |
| 2019 | $261.0m | 0.0% | $246.4m | 94.4% |
| 2018 | $261.0m | +20.2% | $238.3m | 91.3% |
| 2017 | $217.2m | +62.6% | $183.6m | 84.5% |
| 2016 | $133.6m | — | $109.0m | 81.6% |
The change compares each fiscal year with the one before. Operating margin is operating profit over revenue from the same filing. Figures are in millions of US dollars, except per-share amounts.
Innoviva revenue compared with its sector
By revenue for its latest fiscal year, Innoviva ranks 203rd of the 422 US health care companies with a page on Celsmar. The sector median grew 11.7% in its latest fiscal year; Innoviva, 14.7%.
| Rank | Company | Revenue | Revenue growth |
|---|---|---|---|
| 201st | Certara | $418.8m | 8.7% |
| 202nd | MiMedx Group | $418.6m | 20.0% |
| 203rd | Innoviva | $411.3m | 14.7% |
| 204th | Ardelyx | $407.3m | 22.1% |
| 205th | Immunocore | $400.0m | 29.0% |
Each amount is in the currency the company reports in; the rank converts them to US dollars at the 16 November 2026 exchange rate. The rest are in US health care stocks.
Questions about the revenue of Innoviva
- How much revenue did Innoviva make in fiscal 2025?
- Innoviva reported revenue of $411.3m for fiscal 2025, compared with $358.7m in fiscal 2024.
- How much has the revenue of Innoviva grown?
- Between fiscal 2016 and fiscal 2025 it went from $133.6m to $411.3m: 208.0% more, an average growth of 13.3% a year.
- What was the best year for revenue at Innoviva?
- Of its last 10 fiscal years, fiscal 2025, with $411.3m.
- Where does Innoviva rank in its sector by revenue?
- It ranks 203rd of the 422 US health care companies with a page on Celsmar, by revenue for its latest fiscal year.
- Where do the figures for Innoviva come from?
- From the annual report (Form 10-K) that Innoviva files with the SEC, the US securities regulator. Each fiscal year links to its filing.
Where each figure comes from
From the annual report (Form 10-K) that Innoviva files with the SEC. The filing for each fiscal year: 2025 · 2024 · 2023 · 2022 · 2021 · 2020 · 2019 · 2018 · 2017 · 2016. More on Innoviva: the Innoviva page · annual accounts · net income · insider transactions.
Information prepared from the accounts the company files with the regulator, for information purposes only. It is not financial advice or a recommendation to buy or sell. Updated on 12 November 2026.